Thermo Fisher Scientific Inc. (NYSE: TMO) held its 2026 Investor Day, where executives outlined the company's growth strategy and financial targets, according to a company statement.

The Waltham, Massachusetts-based company projects 7% organic revenue compound annual growth rate and low-teens adjusted earnings per share growth over the long term. Chairman and CEO Marc Casper said the company serves a $255 billion market with improving demand trends.

"Our customers value Thermo Fisher as their trusted partner," Casper stated. "Our unique scale and depth of capabilities advance scientific discovery and position us incredibly well in an increasingly AI-enabled world."

The company highlighted its Practical Process Improvement Business System, which focuses on continuous improvement across operations. Thermo Fisher operates through brands including Thermo Scientific, Applied Biosystems, Invitrogen, and Fisher Scientific.

Executives emphasized artificial intelligence as a growth driver, stating AI will accelerate scientific breakthroughs and improve productivity in drug discovery. The company claims positioning across the full drug development value chain to capture AI-driven growth.

Thermo Fisher reported annual revenue exceeding $45 billion. The company maintains a strategy combining strategic mergers and acquisitions with capital returns to shareholders.

The presentation materials are available on the company's investor relations website. Thermo Fisher serves customers in life sciences research, analytical challenges, laboratory productivity, diagnostics, and therapy development and manufacturing.